WCI

RI Related News

게시글 목록
No TItle Name Date Hit
815 Construction of China's First Domestic Medical Isotope Test Reactor Starts WCI Secretariat 2024/03/11 189
814 Rosatom Building for Obninsk Radiopharmaceutical Plant Completed WCI Secretariat 2024/03/11 177
813 Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform WCI Secretariat 2024/03/11 179
812 Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177 WCI Secretariat 2024/03/11 175
811 AlphaGen Therapeutics and ARTBIO Announced Exclusive Strategic Collaboration for the Development and Commercialization of AB001 in Greater China and on ARTBIO’s 212Pb AlphaDirect™ Technology WCI Secretariat 2024/03/11 190
810 Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy WCI Secretariat 2024/03/11 169
809 PanTera Signed Agreement with Bayer for the Supply of Actinium-225 WCI Secretariat 2024/03/11 182
808 RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in Gastroenteropancreatic Neuroendocrine Tumors WCI Secretariat 2024/03/11 175
807 Life Molecular Imaging and Oryx Isotopes Industrial Company announced a Strategic Partnership for the Production and Distribution of Florbetaben (18F) in the Kingdom of Saudi Arabia and Other Countries in Reach WCI Secretariat 2024/03/11 177
806 ITM and Alpha-9 Oncology Announced Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program WCI Secretariat 2024/03/11 187
805 Orano Med Lays Foundations for New Manufacturing Site for the Production of lead-212 Radioligand Therapies WCI Secretariat 2024/03/11 187
804 Zeno Power Secures Radioisotope Fuel Supply from DOE to Build Full-Scale RPSs WCI Secretariat 2024/03/11 201
803 First Targeted Alpha Therapy Wins FDA Breakthrough Device Designation RadioMedix and Orano Med’s Radioligand Therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial WCI Secretariat 2024/03/11 186
802 ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radio theranostics WCI Secretariat 2024/01/08 325
801 Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses WCI Secretariat 2024/01/08 327
First Prev 1 2 3 4 5 6 7 8 9 10 End (55 Page)

비밀글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.